{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:41:25Z","timestamp":1793155285195,"version":"4.5.0"},"reference-count":117,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2022.0067","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T07:29:24Z","timestamp":1643786964000},"source":"Crossref","is-referenced-by-count":18,"title":["Paradoxical reactions to biologicals in chronic inflammatory systemic diseases"],"prefix":"10.3238","author":[{"given":"Igor","family":"Kremenevski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sticherling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Raithel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"10.3238\/arztebl.m2022.0067_ref1","doi-asserted-by":"crossref","unstructured":"Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P: Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 644&#8211;59.","DOI":"10.1038\/ajg.2011.73"},{"key":"10.3238\/arztebl.m2022.0067_ref2","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020; 79: 685&#8211;99."},{"key":"10.3238\/arztebl.m2022.0067_ref3","doi-asserted-by":"crossref","unstructured":"Li SJ, Perez-Chada LM, Merola JM: TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management. J Psoriasis Psoriatic Arthritis 2019; 4: 70&#8211;80.","DOI":"10.1177\/2475530318810851"},{"key":"10.3238\/arztebl.m2022.0067_ref4","doi-asserted-by":"crossref","unstructured":"Abramowicz D, Schandene L, Goldman M, et al.: Release of tumour necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606&#8211;8.","DOI":"10.1097\/00007890-198904000-00008"},{"key":"10.3238\/arztebl.m2022.0067_ref5","doi-asserted-by":"crossref","unstructured":"Khan DA: Hypersensitivity and immunologic reactions to biologicals: opportunities for the allergist. Ann Allergy Asthma Immunol 2016; 117: 115&#8211;20.","DOI":"10.1016\/j.anai.2016.05.013"},{"key":"10.3238\/arztebl.m2022.0067_ref6","doi-asserted-by":"crossref","unstructured":"G\u00fclsen A, Wedi B, Jappe U: Hypersensitivity reactions to biologicals (part I): allergy as an important differential diagnosis in complex immune-derived adverse events. Allergo J Int 2020; 29: 97&#8211;125.","DOI":"10.1007\/s40629-020-00126-6"},{"key":"10.3238\/arztebl.m2022.0067_ref7","unstructured":"Richter B, Sander O, Zink A, et al.: Biotechnologisch hergestellte Arzneimittel in der Zweitlinientherapie bei der rheumatoiden Arthritis IQWiG-Berichte &#8211; Nr. 180 A10&#8211;01 1.0 28.06.2013."},{"key":"10.3238\/arztebl.m2022.0067_ref8","doi-asserted-by":"crossref","unstructured":"G\u00fclsen A, Wedi B, Jappe U: Hypersensitivity reactions to biologicals (part II): allergy as an important differential diagnosis in complex immune-derived adverse events. Allergo J Int 2020; 29: 139&#8211;54.","DOI":"10.1007\/s40629-020-00127-5"},{"key":"10.3238\/arztebl.m2022.0067_ref9","doi-asserted-by":"crossref","unstructured":"Pichler WJ: Adverse side-effects to biological agents. Allergy 2006; 61: 912&#8211;20.","DOI":"10.1111\/j.1398-9995.2006.01058.x"},{"key":"10.3238\/arztebl.m2022.0067_ref10","doi-asserted-by":"crossref","unstructured":"Decock A, Van Assche G, Vermeire S, Wuyts W, Ferrante M: Sarcoidosis-like lesions: another paradoxical reaction to anti-TNF therapy? J Crohns Colitis 2017; 11: 378&#8211;83.","DOI":"10.1093\/ecco-jcc\/jjw155"},{"key":"10.3238\/arztebl.m2022.0067_ref11","doi-asserted-by":"crossref","unstructured":"Murdaca G, Span\u00f2 F, Contatore M, et al.: Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin Drug Saf 2016; 15: 43&#8211;52.","DOI":"10.1517\/14740338.2016.1112375"},{"key":"10.3238\/arztebl.m2022.0067_ref12","unstructured":"Puxeddu I, Caltran E, Rocchi V, Del Corso I, Tavoni A, Migliorini P: Hypersensitivity reactions during treatment with biological agents. Clin Exp Rheumatol 2016; 34: 129&#8211;32."},{"key":"10.3238\/arztebl.m2022.0067_ref13","doi-asserted-by":"crossref","unstructured":"Fauny M, Moulin D, D&#8217;Amico F, et al.: Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis 2020; 79: 1132&#8211;8.","DOI":"10.1136\/annrheumdis-2020-217927"},{"key":"10.3238\/arztebl.m2022.0067_ref14","doi-asserted-by":"crossref","unstructured":"Preidl RH, Ebker T, Raithel M, Wehrhan F, Neukam FW, Stockmann P: Osteonecrosis of the jaw in a Crohn&#8217;s disease patient following a course of bisphosphonate and adalimumab therapy: a case report. BMC Gastroenterol 2014; 14: 6.","DOI":"10.1186\/1471-230X-14-6"},{"key":"10.3238\/arztebl.m2022.0067_ref15","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez MV, Meineri M, Sanmart\u00ed R: Skin lesions and treatment with tumor necrosis factor alpha antagonists. Reumatol Clin 2013; 9: 53&#8211;61.","DOI":"10.1016\/j.reumae.2012.07.008"},{"key":"10.3238\/arztebl.m2022.0067_ref16","doi-asserted-by":"crossref","unstructured":"Harrison MJ, Dixon WG, Watson KD, et al.: Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68: 209&#8211;15.","DOI":"10.1136\/ard.2007.087288"},{"key":"10.3238\/arztebl.m2022.0067_ref17","doi-asserted-by":"crossref","unstructured":"Rahier JF, Buche S, Peyrin-Biroulet L, et al.: Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol 2010; 8: 1048&#8211;55.","DOI":"10.1016\/j.cgh.2010.07.022"},{"key":"10.3238\/arztebl.m2022.0067_ref18","doi-asserted-by":"crossref","unstructured":"Bernstein CN, Wajda A, Blanchard JF: The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005; 129: 827&#8211;36.","DOI":"10.1053\/j.gastro.2005.06.021"},{"key":"10.3238\/arztebl.m2022.0067_ref19","doi-asserted-by":"crossref","unstructured":"Thiebault H, Boyard-Lasselin P, Guignant C, et al.: Paradoxical articular manifestations in patients with IBD treated with infliximab. Eur J Gastroenterol Hepatol 2016; 28: 876&#8211;81.","DOI":"10.1097\/MEG.0000000000000643"},{"key":"10.3238\/arztebl.m2022.0067_ref20","doi-asserted-by":"crossref","unstructured":"Bae JM, Lee HH, Lee BI, et al.: Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. Aliment Pharmacol Ther 2018; 48: 196&#8211;205.","DOI":"10.1111\/apt.14822"},{"key":"10.3238\/arztebl.m2022.0067_ref21","doi-asserted-by":"crossref","unstructured":"Puig L: Paradoxical reactions: Anti-TNF alpha agents, ustekinumab, secukinumab, ixekizumab and others. Curr Probl Dermatol 2018; 53: 49&#8211;63.","DOI":"10.1159\/000479475"},{"key":"10.3238\/arztebl.m2022.0067_ref22","doi-asserted-by":"crossref","unstructured":"Durel CA, Feuer E, Pialat JB, Berthoux E, Chapurlat RD, Confavreux CB : Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis. BMC Neurol 2013; 13: 212.","DOI":"10.1186\/1471-2377-13-212"},{"key":"10.3238\/arztebl.m2022.0067_ref23","doi-asserted-by":"crossref","unstructured":"Miyagi R, Ideguchi H, Soga T, et al.: Development of pulmonary and cardiac sarcoidosis during etanercept therapy. Int J Rheum Dis 2014; 17: 810&#8211;2.","DOI":"10.1111\/1756-185X.12178"},{"key":"10.3238\/arztebl.m2022.0067_ref24","doi-asserted-by":"crossref","unstructured":"Strik AS, van den Brink GR, Ponsioen C, Mathot R, L\u00f6wenberg M, D&#8217;Haens GR: Suppression of anti&#8208;-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2017; 45: 1128&#8211;34.","DOI":"10.1111\/apt.13994"},{"key":"10.3238\/arztebl.m2022.0067_ref25","doi-asserted-by":"crossref","unstructured":"Thomas SS, Borazan N, Barroso N, et al.: Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs 2015; 29: 241&#8211;58.","DOI":"10.1007\/s40259-015-0134-5"},{"key":"10.3238\/arztebl.m2022.0067_ref26","doi-asserted-by":"crossref","unstructured":"Matsumoto S, Mashima H: Efficiacy of ustekinumab against IFX-induced psoriasis and arthritis associated with Crohn&#8216;s disease. Biologics 2018; 12: 69&#8211;73.","DOI":"10.2147\/BTT.S169326"},{"key":"10.3238\/arztebl.m2022.0067_ref27","doi-asserted-by":"crossref","unstructured":"Tillack C, Ehmann LM, Friedrich M, et al.: Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-&#947;-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment. Gut 2014; 63: 567&#8211;77.","DOI":"10.1136\/gutjnl-2012-302853"},{"key":"10.3238\/arztebl.m2022.0067_ref28","doi-asserted-by":"crossref","unstructured":"Toussirot E, Aubin F: Paradoxical reactions under TNF-&#945; blocking agents and other biological agents given for chronic immune mediated diseases: an analytical and comprehensive overview. RMD Open 2016; 2: e000239.","DOI":"10.1136\/rmdopen-2015-000239"},{"key":"10.3238\/arztebl.m2022.0067_ref29","doi-asserted-by":"crossref","unstructured":"Puig L, Morales-M\u00fanera CE, L\u00f3pez-Ferrer A, Geli C: Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriasis arthritis: a case report and review. Dermatology 2012; 225: 14&#8211;7.","DOI":"10.1159\/000339864"},{"key":"10.3238\/arztebl.m2022.0067_ref30","doi-asserted-by":"crossref","unstructured":"Benzaquen M, Flachaire B, Rouby F, Berbis P, Guis S: Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn&#8216;s disease-associated spondyloarthropathy. Rheumatol Int 2018; 38: 1297&#8211;9.","DOI":"10.1007\/s00296-018-4034-0"},{"key":"10.3238\/arztebl.m2022.0067_ref31","doi-asserted-by":"crossref","unstructured":"Faivre C, Villani AP, Aubin F, et al.: Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biological agents (BA) used in chronic inflammatory diseases. J Am Acad Dermatol 2016; 74: 1153&#8211;9.","DOI":"10.1016\/j.jaad.2016.01.018"},{"key":"10.3238\/arztebl.m2022.0067_ref32","doi-asserted-by":"crossref","unstructured":"Hutchings D, Miller JA, Voltaggio L: Paradoxical gastrointestinal reactions in patients taking tumor necrosis factor inhibitors: a rare event that broadens the histologic spectrum of medication associated injury. Hum Pathol 2019; 85: 202&#8211;9.","DOI":"10.1016\/j.humpath.2018.11.003"},{"key":"10.3238\/arztebl.m2022.0067_ref33","doi-asserted-by":"crossref","unstructured":"Krishnan A, Stobaugh DJ, Deepak P: Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-apha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis. Rheumatol Int&nbsp;2015; 35: 661&#8211;8.","DOI":"10.1007\/s00296-014-3133-9"},{"key":"10.3238\/arztebl.m2022.0067_ref34","doi-asserted-by":"crossref","unstructured":"Gawdzik A, Ponikowska M, Jankowska-Konsur A, Wo&#378;niak Z, Maj J, Szepietowski JC: Paradoxical skin reaction to certolizumab, an overlap of pyoderma gangrenosum and psoriasis in a young woman treated for ankylosing spondylitis: case report with literature review. Dermatol Ther (Heidelb) 2020; 10: 869&#8211;79.","DOI":"10.1007\/s13555-020-00398-4"},{"key":"10.3238\/arztebl.m2022.0067_ref35","doi-asserted-by":"crossref","unstructured":"Schneider AM, Weghuber D, Hetzer B, et al.: Vedolizumab use after failure of TNF-&#945; antagonists in children and adolescents with inflammatory bowel disease. BMC Gastroenterol 2018; 18: 140.","DOI":"10.1186\/s12876-018-0868-x"},{"key":"10.3238\/arztebl.m2022.0067_ref36","doi-asserted-by":"crossref","unstructured":"Kearsley-Fleet L, Z\u00e1vada J, Hetland ML, et al.: The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. Rheumatology (Oxford) 2015; 54: 1074&#8211;9.","DOI":"10.1093\/rheumatology\/keu446"},{"key":"10.3238\/arztebl.m2022.0067_ref37","doi-asserted-by":"crossref","unstructured":"Moulis G, Sommet A, Lapeyre-Mestre M, Montastruc JL, Association Fran\u00e7aise des Centres R\u00e9gionaux de PharmacoVigilance: Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case\/non-case study in a nationwide pharmacovigilance database. Rheumatology (Oxford) 2014; 53: 1864&#8211;71.","DOI":"10.1093\/rheumatology\/keu214"},{"key":"10.3238\/arztebl.m2022.0067_ref38","doi-asserted-by":"crossref","unstructured":"Pastore S, Naviglio S, Canuto A, et al.: Serious adverse events associated with anti-tumor necrosis factor alpha agents in pediatric-onset inflammatory bowel disease and juvenile idiopathic arthritis in a real-life setting. Paediatr Drugs 2018; 20: 165&#8211;71.","DOI":"10.1007\/s40272-017-0267-8"},{"key":"10.3238\/arztebl.m2022.0067_ref39","doi-asserted-by":"crossref","unstructured":"Saint Marcoux B, De Bandt M, CRI (Club Rhumatismes et Inflammation): Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 2006; 73: 710&#8211;3.","DOI":"10.1016\/j.jbspin.2006.02.010"},{"key":"10.3238\/arztebl.m2022.0067_ref40","doi-asserted-by":"crossref","unstructured":"Pu\u00e9chal X, Gottenberg JE, Berthelot JM, et al.: Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: results from the autoimmunity and rituximab registry. Arthritis Care Res (Hoboken) 2012; 64: 331&#8211;9.","DOI":"10.1002\/acr.20689"},{"key":"10.3238\/arztebl.m2022.0067_ref41","doi-asserted-by":"crossref","unstructured":"Caporali R, Crepaldi G, Codullo V, et al.: 20 years of experience with tumour necrosis factor inhibitors: what have we learned? Rheumatology (Oxford) 2018; 57 (Suppl 7) : vii5&#8211;vii10.","DOI":"10.1093\/rheumatology\/key059"},{"key":"10.3238\/arztebl.m2022.0067_ref42","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-De-Lis M, Retamozo S, Flores-Ch\u00e1vez A, et al.: Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opin Drug Saf 2017; 16: 1255&#8211;71.","DOI":"10.1080\/14740338.2017.1372421"},{"key":"10.3238\/arztebl.m2022.0067_ref43","doi-asserted-by":"crossref","unstructured":"de Camargo MC, Barros BCA, Fulone I, et al.: Adverse events in patients with rheumatoid arthritis and psoriatic arthritis receiving long-term biological agents in a real-life setting. Front Pharmacol 2019; 10: 965.","DOI":"10.3389\/fphar.2019.00965"},{"key":"10.3238\/arztebl.m2022.0067_ref44","doi-asserted-by":"crossref","unstructured":"Vultaggio A, Matucci A, Nencini F, et al.: Anti-infliximab IgE and non-IgE antibodies and induction of infusion related severe anaphylactic reactions. Allergy 2010; 65: 657&#8211;61.","DOI":"10.1111\/j.1398-9995.2009.02280.x"},{"key":"10.3238\/arztebl.m2022.0067_ref45","doi-asserted-by":"crossref","unstructured":"Fiorino G, Danese S, Pariente B, Allez M: Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-&#945; agents. Autoimmun Rev 2014; 13: 15&#8211;9.","DOI":"10.1016\/j.autrev.2013.06.005"},{"key":"10.3238\/arztebl.m2022.0067_ref46","doi-asserted-by":"crossref","unstructured":"Kutluk \u00d6, Enginar A\u00dc, Balci N, B\u00fct\u00fcn B, Kacar C: Skin reactions developing after anti-tumor necrosis factor treatment: a paradoxical side effect. Arch Rheumatol 2019; 34: 100&#8211;4.","DOI":"10.5606\/ArchRheumatol.2019.6882"},{"key":"10.3238\/arztebl.m2022.0067_ref47","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-L\u00f3pez MA, Mart\u00ednez-Taboada VM, Gonz\u00e1lez-Vela MC, Fern\u00e1ndez-Llaca H, Val-Bernal JF: New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra. Br J Dermatol 2008; 158: 1146&#8211;8.","DOI":"10.1111\/j.1365-2133.2008.08470.x"},{"key":"10.3238\/arztebl.m2022.0067_ref48","doi-asserted-by":"crossref","unstructured":"Bilal J, Berlinberg A, Riaz IB, et al.: Risk of infections and cancer in patients with rheumatologic diseases receiving interleukin inhibitors: a systematic review and meta-analysis. JAMA Network Open 2019; 2: e1913102.","DOI":"10.1001\/jamanetworkopen.2019.13102"},{"key":"10.3238\/arztebl.m2022.0067_ref49","doi-asserted-by":"crossref","unstructured":"Kumar S, de Lusignan S, McGovern A, et al.: Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care. BMJ 2018; 360: k342.","DOI":"10.1136\/bmj.k342"},{"key":"10.3238\/arztebl.m2022.0067_ref50","doi-asserted-by":"crossref","unstructured":"Galv\u00e3o VR, Castells MC: Hypersensitivity to biological agents&#8212;updated diagnosis, management, and treatment. J Allergy Clin Immunol Pract 2015; 3: 175&#8211;85.","DOI":"10.1016\/j.jaip.2014.12.006"},{"key":"10.3238\/arztebl.m2022.0067_ref51","unstructured":"Arzneimittelkommission der deutschen \u00c4rzteschaft: &#8222;Aus der UAW-Datenbank&#8220; &#8211; Rezidiv eines Morbus Crohn nach Behandlung einer atopischen Dermatitis mit Dupilumab. Dtsch Arztebl 2019; 116: A-1919."},{"key":"10.3238\/arztebl.m2022.0067_ref52","unstructured":"Fachinformation &#8222;AMGEVITA\u00ae&#8220; (Adalimumab) 20mg\/40mg Injektionsl\u00f6sung in einer Fertigspritze: www.fachkreise.amgen.de\/downloads\/f\/1\/1181\/amgevita-fachinformation.pdf (Stand Februar 2020, last accessed on 8 April 2021)."},{"key":"10.3238\/arztebl.m2022.0067_ref53","unstructured":"Fachinformation &#8222;REMICADE\u00ae&#8220; (Infliximab) 100 mg Pulver f\u00fcr ein Konzentrat zur Herstellung einer Infusionsl\u00f6sung: www.msd.de\/fileadmin\/files\/fachinformationen\/remicade.pdf (Stand October 2020, last accessed on 8 April 2021)."},{"key":"10.3238\/arztebl.m2022.0067_ref54","unstructured":"Fachinformation &#8222;Simponi\u00ae&#8220; (Golimumab) 50 mg Injektionsl\u00f6sung Vorgef\u00fcllter Injektor\/Fertigspritze: www.msd.de\/fileadmin\/files\/fachinformationen\/simponi_injektor_spritze_50mg.pdf (Stand October 2020, last accessed on 8 April 2021)."},{"key":"10.3238\/arztebl.m2022.0067_ref55","unstructured":"Fachinformation &#8222;Cimzia\u00ae&#8220; (Certolizumab Pegol) 200 mg Injektionsl\u00f6sung in einer Fertigspritze: www.fachinfo.de\/pdf\/012884 (Stand October 2020, last accessed on 8 April 2021)."},{"key":"10.3238\/arztebl.m2022.0067_ref56","doi-asserted-by":"crossref","unstructured":"Torres T, Vila\u00e7a S, Velho G, Selores M: Etanercept-induced asthma in a psoriatic patient resolving with transition to Ustekinumab. Eur J Dermatol 2012; 22: 696&#8211;7.","DOI":"10.1684\/ejd.2012.1816"},{"key":"10.3238\/arztebl.m2022.0067_ref57","doi-asserted-by":"crossref","unstructured":"McDonnell MJ, Rutherford RM, O&#8216;Regan A: Sarcoidosis complicating treatment with adalimumab for Crohn&#8217;s disease. J Crohn&#8217;s Colitis 2014; 8: 1140&#8211;1.","DOI":"10.1016\/j.crohns.2014.02.006"},{"key":"10.3238\/arztebl.m2022.0067_ref58","doi-asserted-by":"crossref","unstructured":"Toussirot \u00c9, Houvenagel \u00c9, Go\u00ebb V, et al.: Development of inflammatory bowel disease during anti-TNF-&#945; therapy for inflammatory rheumatic disease: a nationwide series. Joint Bone Spine 2012; 79: 457&#8211;63.","DOI":"10.1016\/j.jbspin.2011.10.001"},{"key":"10.3238\/arztebl.m2022.0067_ref59","doi-asserted-by":"crossref","unstructured":"Dogra S, Bishnoi A, Narang T, Handa S: Secukinumab-induced paradoxical pustular psoriasis. Clin Exp Dermatol 2019; 44: 72&#8211;3.","DOI":"10.1111\/ced.13731"},{"key":"10.3238\/arztebl.m2022.0067_ref60","doi-asserted-by":"crossref","unstructured":"Nakao M, Asano Y, Kamata M, Yoshizaki A, Sato S: Successful treatment of palmoplantar pustular psoriasis with brodalumab. Eur J Dermatol 2018; 28: 538&#8211;9.","DOI":"10.1684\/ejd.2018.3325"},{"key":"10.3238\/arztebl.m2022.0067_ref61","doi-asserted-by":"crossref","unstructured":"Denadai R, Teixeira FV, Steinwurz F, Romiti R, Saad-Hossne R: Induction or exacerbation of psoriatic lesions during anti-TNF-&#945; therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis 2013; 7: 517&#8211;24.","DOI":"10.1016\/j.crohns.2012.08.007"},{"key":"10.3238\/arztebl.m2022.0067_ref62","doi-asserted-by":"crossref","unstructured":"Ishiuji Y, Umezawa Y, Asahina A, et al.: Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: report of two cases. J Dermatol 2018; 45: 732&#8211;4.","DOI":"10.1111\/1346-8138.14295"},{"key":"10.3238\/arztebl.m2022.0067_ref63","doi-asserted-by":"crossref","unstructured":"Cleynen I, Vermeire S: Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol 2012; 9: 496&#8211;503.","DOI":"10.1038\/nrgastro.2012.125"},{"key":"10.3238\/arztebl.m2022.0067_ref64","doi-asserted-by":"crossref","unstructured":"Zeitz J, Enderlin S, Biedermann L, et al.: New onset, aggravation and recurrence of Crohn&#8217;s disease upon treatment with three different tumor necrosis factor inhibitors. Case Rep Gastroenterol 2015; 9: 106&#8211;12.","DOI":"10.1159\/000381637"},{"key":"10.3238\/arztebl.m2022.0067_ref65","doi-asserted-by":"crossref","unstructured":"Wang J, Bhatia A, Krugliak Cleveland N, et al.: Rapid onset of inflammatory bowel disease after receiving secukinumab infusion. ACG Case Rep J 2018; 5: e56.","DOI":"10.14309\/crj.2018.56"},{"key":"10.3238\/arztebl.m2022.0067_ref66","doi-asserted-by":"crossref","unstructured":"Bailly E, Von Tokarski F, Beau-Salinas F, et al.: Interstitial nephritis secondary to vedolizumab treatment in Crohn&#8217;s disease and safe rechallenge using steroids: a case report. Am J Kidney Dis 2017; 71: 142&#8211;5.","DOI":"10.1053\/j.ajkd.2017.08.008"},{"key":"10.3238\/arztebl.m2022.0067_ref67","unstructured":"Fachinformation &#8222;ENTYVIO\u00ae&#8220; (Vedolizumab) 300 mg Pulver f\u00fcr ein Konzentrat zur Herstellung einer Infusionsl\u00f6sung: www.fachinfo.de\/suche\/fi\/020200 (Stand October 2020, last accessed on 8 April 2021)."},{"key":"10.3238\/arztebl.m2022.0067_ref68","doi-asserted-by":"crossref","unstructured":"Lopetuso LR, Mocci G, Marzo M, et al.: Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-&#945; on the liver. Int J Mol Sci 2018; 19: 2199.","DOI":"10.3390\/ijms19082199"},{"key":"10.3238\/arztebl.m2022.0067_ref69","doi-asserted-by":"crossref","unstructured":"Bosch X, Saiz A, Ramos-Casals M: BIOGEAS study group: monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol 2011; 7: 165&#8211;72.","DOI":"10.1038\/nrneurol.2011.1"},{"key":"10.3238\/arztebl.m2022.0067_ref70","doi-asserted-by":"crossref","unstructured":"Piga M, Chessa E, Ibba V, et al.: Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort. Autoimmun Rev 2014; 13: 873&#8211;9.","DOI":"10.1016\/j.autrev.2014.05.005"},{"key":"10.3238\/arztebl.m2022.0067_ref71","doi-asserted-by":"crossref","unstructured":"Ishikawa Y, Yukawa N, Ohmura K, et al.: Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol 2010; 29: 563&#8211;6.","DOI":"10.1007\/s10067-009-1370-1"},{"key":"10.3238\/arztebl.m2022.0067_ref72","doi-asserted-by":"crossref","unstructured":"Garcovich S, De Simone C, Genovese G, Berti E, Cugno M, Marzano AV: Paradoxical skin reactions to biologics in patients with rheumatologic disorders. Front Pharmacol 2019; 10: 282.","DOI":"10.3389\/fphar.2019.00282"},{"key":"10.3238\/arztebl.m2022.0067_ref73","doi-asserted-by":"crossref","unstructured":"Aghdashi MA, Khadir M, Dinparasti-Saleh R: Antinuclear antibodies and lupus-like manifestations in rheumatoid arthritis and ankylosing spondylitis patients at 4 months&#8216; follow-up after treatment with infliximab and etanercept. Curr Rheumatol Rev 2020; 16: 61&#8211;6.","DOI":"10.2174\/1573397115666190506152729"},{"key":"10.3238\/arztebl.m2022.0067_ref74","doi-asserted-by":"crossref","unstructured":"Arnaud L, Mertz P, Gavand PE, et al.: Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. Ann Rheum Dis 2019; 78: 504&#8211;8.","DOI":"10.1136\/annrheumdis-2018-214598"},{"key":"10.3238\/arztebl.m2022.0067_ref75","doi-asserted-by":"crossref","unstructured":"Giezen TJ, Mantel-Teeuwisse AK, Meyboom RH, Straus SM, Leufkens HG, Egberts TC: Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Drug Saf 2010; 33: 865&#8211;78.","DOI":"10.2165\/11538330-000000000-00000"},{"key":"10.3238\/arztebl.m2022.0067_ref76","doi-asserted-by":"crossref","unstructured":"Kumar N, Abboud H: Iatrogenic CNS demyelination in the era of modern biologics. Mult Scler 2019; 25: 1079&#8211;85.","DOI":"10.1177\/1352458519828601"},{"key":"10.3238\/arztebl.m2022.0067_ref77","doi-asserted-by":"crossref","unstructured":"G\u00e4wert L, Hierse F, Zink A, Strangfeld A: How well do patient reports reflect adverse drug reactions reported by rheumatologists? Agreement of physician- and patient-reported adverse events in patients with rheumatoid arthritis observed in the German biologics register. Rheumatology (Oxford) 2011; 50: 152&#8211;60.","DOI":"10.1093\/rheumatology\/keq300"},{"key":"10.3238\/arztebl.m2022.0067_ref78","doi-asserted-by":"crossref","unstructured":"Sim DW, Park KH, Park HJ, et al.: Clinical characteristics of adverse events associated with therapeutic monoclonal antibodies in Korea. Pharmacoepidemiol Drug Saf 2016; 25: 1279&#8211;86.","DOI":"10.1002\/pds.4049"},{"key":"10.3238\/arztebl.m2022.0067_ref79","doi-asserted-by":"crossref","unstructured":"de Camargo MC, Barros BCA, Fulone I, et al.: Adverse events in patients with rheumatoid arthritis and psoriatic arthritis receiving long-term biological agents in a real-life setting. Front Pharmacol 2019; 10: 965.","DOI":"10.3389\/fphar.2019.00965"},{"key":"10.3238\/arztebl.m2022.0067_ref80","unstructured":"Fachinformation &#8222;Enbrel\u00ae&#8220; (Etanercept) 25 mg\/ 50 mg Injektionsl\u00f6sung in Fertigspritze: www.pfizer.de\/sites\/default\/files\/FI-9967.pdf (Stand September 2020, last accessed on 8 April 2021)."},{"key":"10.3238\/arztebl.m2022.0067_ref81","doi-asserted-by":"crossref","unstructured":"Andrade P, Lopes S, Gaspar R, Nunes A, Magina S, Macedo G: Anti-tumor necrosis factor-&#945;-induced dermatological complications in a large cohort of inflammatory bowel disease patients. Dig Dis Sci 2018; 63: 746&#8211;54.","DOI":"10.1007\/s10620-018-4921-y"},{"key":"10.3238\/arztebl.m2022.0067_ref82","doi-asserted-by":"crossref","unstructured":"Tuchinda P, Bremmer M, Gaspari AA: A case series of refractory cutaneous sarcoidosis successfully treated with infliximab. Dermatol Ther (Heidelb) 2012; 2: 11.","DOI":"10.1007\/s13555-012-0011-9"},{"key":"10.3238\/arztebl.m2022.0067_ref83","doi-asserted-by":"crossref","unstructured":"Igarashi A, Kato T, Kato M, Song M, Nakagawa H, Japanese Ustekinumab Study Group: Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2\/3 clinical trial. J Dermatol 2012; 39: 242&#8211;52.","DOI":"10.1111\/j.1346-8138.2011.01347.x"},{"key":"10.3238\/arztebl.m2022.0067_ref84","doi-asserted-by":"crossref","unstructured":"Papp KA, Gordon KB, Langley RG, et al.: Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol 2018; 179: 320&#8211;8.","DOI":"10.1111\/bjd.16464"},{"key":"10.3238\/arztebl.m2022.0067_ref85","doi-asserted-by":"crossref","unstructured":"Colombel JF, Sands BE, Rutgeerts P, et al.: The safety of vedolizumab for ulcerative colitis and Crohn&#8217;s disease. Gut 2017; 66: 839&#8211;51.","DOI":"10.1136\/gutjnl-2015-311079"},{"key":"10.3238\/arztebl.m2022.0067_ref86","doi-asserted-by":"crossref","unstructured":"Bae JM, Kim M, Lee HH, et al.: Increased risk of vitiligo following anti-tumor necrosis factor therapy: a 10-year population-based cohort study. J Invest Dermatol 2018; 138: 768&#8211;74.","DOI":"10.1016\/j.jid.2017.11.012"},{"key":"10.3238\/arztebl.m2022.0067_ref87","doi-asserted-by":"crossref","unstructured":"Del Giorno R, Iodice A, Mangas C, Gabutti L: New-onset cutaneous sarcoidosis under tocilizumab treatment for giant cell arteritis: a quasi-paradoxical adverse drug reaction. Case report and literature review. Ther Adv Musculoskelet Dis 2019; 11: 1&#8211;6.","DOI":"10.1177\/1759720X19841796"},{"key":"10.3238\/arztebl.m2022.0067_ref88","doi-asserted-by":"crossref","unstructured":"Caravello S, Moggio E, Soglia S, Zane C: Paradoxical reaction to brodalumab in a patient affected by psoriasis. Ital J Dermatol Venerol 2021; 156: 511&#8211;2.","DOI":"10.23736\/S2784-8671.21.06801-8"},{"key":"10.3238\/arztebl.m2022.0067_ref89","doi-asserted-by":"crossref","unstructured":"Jeong KM, Seo JY, Kim A, Baek YS, Song HJ, Jeon J: Tumor necrosis factor-alpha inhibitor-associated psoriatic alopecia in a patient with ulcerative colitis: a case report and review of the literature. Ann Dermatol 2021; 33: 82&#8211;5.","DOI":"10.5021\/ad.2021.33.1.82"},{"key":"10.3238\/arztebl.m2022.0067_ref90","doi-asserted-by":"crossref","unstructured":"da Silva Cendon Duran C, Barreto Santiago M: Cutaneous vasculitis during secukinumab treatment. Eur J Case Rep Intern Med 2020; 7: 001815.","DOI":"10.12890\/2020_001815"},{"key":"10.3238\/arztebl.m2022.0067_ref91","doi-asserted-by":"crossref","unstructured":"Fouache D, Goeb V, Massy-Guillement N, et al.: Paradoxical adverse events of anti-tumour necrosis factor therapy for spondylarthropathies: a retrospective study. Rheumatology (Oxford) 2009; 48: 761&#8211;4.","DOI":"10.1093\/rheumatology\/kep083"},{"key":"10.3238\/arztebl.m2022.0067_ref92","doi-asserted-by":"crossref","unstructured":"Hernandez MV, Sanmarti R, Canete JD, et al.: Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Arthritis Care Res (Hoboken) 2013; 65: 2024&#8211;31.","DOI":"10.1002\/acr.22096"},{"key":"10.3238\/arztebl.m2022.0067_ref93","doi-asserted-by":"crossref","unstructured":"de Gannes GC, Ghoreishi M, Pope J, et al.: Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007; 143: 223&#8211;31.","DOI":"10.1001\/archderm.143.2.223"},{"key":"10.3238\/arztebl.m2022.0067_ref94","doi-asserted-by":"crossref","unstructured":"Brunasso AM, Laimer M, Massone C: Paradoxical reactions to targeted biological treatments: a way to treat and trigger? Acta Derm Venerol 2010; 90: 183&#8211;5.","DOI":"10.2340\/00015555-0777"},{"key":"10.3238\/arztebl.m2022.0067_ref95","unstructured":"Joyau C, Veyrac G, Dixneuf V, Jolliet P: Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol 2012; 30: 700&#8211;6."},{"key":"10.3238\/arztebl.m2022.0067_ref96","doi-asserted-by":"crossref","unstructured":"Cleynen I, Van Moerkercke W, Billiet T, et al.: Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med 2016; 164: 10&#8211;22.","DOI":"10.7326\/M15-0729"},{"key":"10.3238\/arztebl.m2022.0067_ref97","doi-asserted-by":"crossref","unstructured":"Thomas L, Canoui-Poitrine F, Gottenberg JE, et al.: Incidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: data from the French AIR registry. J Rheumatol 2012; 39: 893&#8211;8.","DOI":"10.3899\/jrheum.111347"},{"key":"10.3238\/arztebl.m2022.0067_ref98","doi-asserted-by":"crossref","unstructured":"van Dijken TD, Vastert SJ, Gerloni VM, et al.: Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 2011; 38: 1441&#8211;6.","DOI":"10.3899\/jrheum.100809"},{"key":"10.3238\/arztebl.m2022.0067_ref99","doi-asserted-by":"crossref","unstructured":"Terreaux W, Masson C, Eschard JP, et al.: Incidence of paradoxical reactions in patients treated with tocilizumab for rheumatoid arthritis: data from the French registry REGATE. Joint Bone Spine 2018; 85: 53&#8211;7.","DOI":"10.1016\/j.jbspin.2017.01.002"},{"key":"10.3238\/arztebl.m2022.0067_ref100","doi-asserted-by":"crossref","unstructured":"Korzenik J, Larsen MD, Nielsen J, Kjeldsen J, N\u00f8rg\u00e5rd BM: Increased risk of developing Crohn&#8216;s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNF&#945; agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Aliment Pharmacol Ther 2019; 50: 289&#8211;94.","DOI":"10.1111\/apt.15370"},{"key":"10.3238\/arztebl.m2022.0067_ref101","doi-asserted-by":"crossref","unstructured":"Fr\u00e9ling E, Baumann C, Cuny JF, et al.: Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel diseases: a 14-year experience. Am J Gastroenterol 2015; 110: 1186&#8211;96.","DOI":"10.1038\/ajg.2015.205"},{"key":"10.3238\/arztebl.m2022.0067_ref102","doi-asserted-by":"crossref","unstructured":"Guerra I, P\u00e9rez-Jeldres T, Iborra M, et al.: Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis 2016; 22: 894&#8211;901.","DOI":"10.1097\/MIB.0000000000000757"},{"key":"10.3238\/arztebl.m2022.0067_ref103","doi-asserted-by":"crossref","unstructured":"Sondermann W, Herz S, Sody E, K\u00f6rber A: Dermatological complications of therapy with biologics in inflammatory autoimmune diseases. J Dtsch Dermatol Ges 2019; 17: 1029&#8211;37.","DOI":"10.1111\/ddg.13964"},{"key":"10.3238\/arztebl.m2022.0067_ref104","doi-asserted-by":"crossref","unstructured":"Braun J, Baraliakos X, Listing J, et al.: Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumour necrosis factor agents. Arthritis Rheum 2007; 57: 639&#8211;47.","DOI":"10.1002\/art.22669"},{"key":"10.3238\/arztebl.m2022.0067_ref105","doi-asserted-by":"crossref","unstructured":"Yamada A, Wang J, Komaki Y, Komaki F, Micic D, Sakuraba A: Systematic review with metaanalysis: risk of new onset IBD with the use of anti-interleukin 17 agents. Aliment Pharmacol Ther 2019; 50: 373&#8211;85.","DOI":"10.1111\/apt.15397"},{"key":"10.3238\/arztebl.m2022.0067_ref106","doi-asserted-by":"crossref","unstructured":"Fidder H, Schnitzler F, Ferrante M, et al.: Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501&#8211;8.","DOI":"10.1136\/gut.2008.163642"},{"key":"10.3238\/arztebl.m2022.0067_ref107","doi-asserted-by":"crossref","unstructured":"Merola JF, Espinoza LR, Fleischmann R: Distinguishing rheumatoid arthritis from psoriatic arthritis. RMD Open 2018; 4: e000656.","DOI":"10.1136\/rmdopen-2018-000656"},{"key":"10.3238\/arztebl.m2022.0067_ref108","doi-asserted-by":"crossref","unstructured":"Richter JG, Chehab G, Kiltz U, et al.: [Digital Health in Rheumatology &#8211; Status 2018\/19]. Dtsch Med Wochenschr 2019; 144: 464&#8211;9.","DOI":"10.1055\/a-0740-8773"},{"key":"10.3238\/arztebl.m2022.0067_ref109","doi-asserted-by":"crossref","unstructured":"Wehrmann C, Sondermann W, K\u00f6rber A: [Secukinumab-induced subacute-cutaneous lupus erythematosus]. Hautarzt 2018; 69: 64&#8211;6.","DOI":"10.1007\/s00105-017-4071-8"},{"key":"10.3238\/arztebl.m2022.0067_ref110","unstructured":"Baraliakos AJ, Kivitz AA, Deodhar AA, et al.: Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial X. Clin Exp Rheumatol 2018; 36: 50&#8211;5."},{"key":"10.3238\/arztebl.m2022.0067_ref111","doi-asserted-by":"crossref","unstructured":"Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L: Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohns Colitis 2013; 7: 769&#8211;79.","DOI":"10.1016\/j.crohns.2013.01.009"},{"key":"10.3238\/arztebl.m2022.0067_ref112","doi-asserted-by":"crossref","unstructured":"Liefferinckxa Cl, Verstockt B, GilsA, et al.: Long-term clinical effectiveness of ustekinumab in patients with Crohn&#8217;s disease who failed biologic therapies: a national cohort study. J Crohns Colitis 2019; 13: 1401&#8211;9.","DOI":"10.1093\/ecco-jcc\/jjz080"},{"key":"10.3238\/arztebl.m2022.0067_ref113","doi-asserted-by":"crossref","unstructured":"Biemans VBC, van der Meulen-de Jong AE, van der Woude ChJ, et al.: Ustekinumab for crohn&#8217;s disease: results of the ICC registry, a nationwide prospective observational cohort study. J Crohns Colitis 2020; 14: 33&#8211;45.","DOI":"10.1093\/ecco-jcc\/jjz119"},{"key":"10.3238\/arztebl.m2022.0067_ref114","doi-asserted-by":"crossref","unstructured":"Garcia Garcia MJ, MJ Garc\u00eda Garc\u00eda, Tirado MR, Callizo MEP: Paradoxical arthritis in inflammatory bowel disease patients on ustekinumab treatment. Inflamm Bowel Dis 2019; 25: e89.","DOI":"10.1093\/ibd\/izz019"},{"key":"10.3238\/arztebl.m2022.0067_ref115","doi-asserted-by":"crossref","unstructured":"Guillo L, D&#8217;Amico F, Danese S, Peyrin-Biroulet L: Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review. J Crohns Colitis 2021; 15: 1236&#8211;43.","DOI":"10.1093\/ecco-jcc\/jjaa260"},{"key":"10.3238\/arztebl.m2022.0067_ref116","doi-asserted-by":"crossref","unstructured":"Varkas G, Thevissen K, De Brabanter G, et al.: An induction or flare of arthritis and\/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series. Ann Rheum Dis&nbsp;2017; 76: 878&#8211;81.","DOI":"10.1136\/annrheumdis-2016-210233"},{"key":"10.3238\/arztebl.m2022.0067_ref117","doi-asserted-by":"crossref","unstructured":"Tadbiri, S Peyrin-Biroulet L, Serrero M, et al.: Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther 2018; 47: 485&#8211;93.","DOI":"10.1111\/apt.14419"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2022.0067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T07:30:16Z","timestamp":1643787016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2022.0067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":117,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2022.0067","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]}}}